MitoQ® signs deal with Allergan

MitoQ®’s world-first antioxidant is set to be recognised on a global scale, after the biotech company has signed a deal with leading pharmaceutical firm Allergan.

The world’s first antioxidant that acts directly in the mitochondria, discovered in New Zealand, will be included in the formulation of Allergan’s new SkinMedica® product line, LUMIVIVE®.

It is the first time MitoQ® Ltd. has supplied its patented antioxidant for use in a third-party product range.

MitoQ® is focused on developing innovative supplement and skincare solutions to support mitochondrial health. “Healthy mitochondria are essential to maintaining youthful skin, energy levels, focus and overall wellness,” explains Greg MacPherson, CEO of MitoQ®.

“SkinMedica® is a brand built on science, with scientifically-proven ingredients in their products, and we are thrilled that they believe in the effectiveness of MitoQ and have included it in their new product line.”

The ingredient used in the product range, scientifically referred to as Mitoquinol Mestlate, works to recharge the skin’s essential repair process at night.

MitoQ® is designed to deliver the body’s own natural antioxidant, CoQ10, into the mitochondria, hundreds of times more effectively than any other antioxidant supplement.

The same hero ingredient is used in MitoQ®’s own product range which comprises of both skincare and supplements.